ACUTAAS CHEMICALS – CONCALL HIGHLIGHTS
Battery Chemicals Expansion
– Phase1 capex completed at Jhagadia
– 2000MT capacity for VC and FEC
– Fully tied with 3-year contracts
– Production already commenced
– Revenue ramp through FY27
– Phase2 capex by Q1FY27
– Third product capex ongoing
– Two new products planned FY27
CDMO Pipeline
– 4 products validated commercially
– Under regulatory approval stage
– ₹50–100Cr peak revenue each
– Ramp-up expected by FY28
– 10-year supply contract secured
– Strong global client relationship
Growth Outlook
– FY27 revenue growth ~25%
– Consistent decade-long track record
– Three growth engines driving business
– Pharma CDMO largest contributor
– Battery chemicals ramping up
– Semiconductor recovery underway
Margins & Capex
– EBITDA margin ~34.5–35%
– FY27 capex ~₹90Cr planned
– Includes spillover and maintenance
– R&D expansion under consideration
R&D Expansion
– 10x capacity expansion planned
– Multi-sector R&D capabilities
– Pharma, battery, semiconductor focus
– Long-term innovation pipeline
Management Commentary
– Battery and semi become key engines
– Independent growth by FY28 expected
– CDMO ramp steep post commercialization
– Sustained growth visibility
Final Takeaway
– Strong multi-engine growth model
– High-margin specialty chemicals focus
– Execution key for next phase
Disclaimer
– Not a buy/sell recommendation
